620 results on '"Csajka, Chantal"'
Search Results
102. Intraocular penetration of penciclovir after oral administration of famciclovir: a population pharmacokinetic model
103. Prediction of free imatinib concentrations based on total plasma concentrations in patients with gastrointestinal stromal tumours
104. Population Pharmacokinetic-Pharmacodynamic Modelling of Angiotensin Receptor Blockade in Healthy Volunteers
105. Population pharmacokinetics of fluconazole given for secondary prevention of oropharyngeal candidiasis in HIV-positive patients
106. Pregnancy Outcome Following Exposure to Topical Retinoids: A Multicenter Prospective Study
107. Parametric Approaches in Population Pharmacokinetics.
108. Parametric and Nonparametric Methods in Population Pharmacokinetics: Experts' Discussion on Use, Strengths, and Limitations.
109. Dosing strategies of imipenem in neonates based on pharmacometric modelling and simulation.
110. High anticholinergic burden at admission associated with in‐hospital mortality in older patients: A comparison of 19 different anticholinergic burden scales.
111. Quality of anticholinergic burden scales and their impact on clinical outcomes: a systematic review
112. A population pharmacokinetic model for escitalopram and its major metabolite in depressive patients during the perinatal period: Prediction of infant drug exposure through breast milk
113. Population Pharmacokinetics/Pharmacodynamics of Dabrafenib Plus Trametinib in Patients with BRAF-Mutated Metastatic Melanoma
114. Optimisation of vancomycin exposure in neonates based on the best level of evidence
115. Development and validation of a multiplex UHPLC-MS/MS assay with stable isotopic internal standards for the monitoring of the plasma concentrations of the antiretroviral drugs bictegravir, cabotegravir, doravirine, and rilpivirine in people living with HI
116. The Steps to Therapeutic Drug Monitoring: A Structured Approach Illustrated With Imatinib
117. Enquête « RTO-COVID-19 » : nos soins, nos actions, leurs effets
118. Pharmacokinetic-Pharmacodynamic Profile of Angiotensin II Receptor Antagonists
119. MOESM2 of Population pharmacokinetics and pharmacodynamics of the artesunate–mefloquine fixed dose combination for the treatment of uncomplicated falciparum malaria in African children
120. ADME pathway approach for pharmacogenetic studies of anti-HIV therapy
121. Population pharmacokinetics and effects of efavirenz in patients with human immunodeficiency virus infection
122. Auteurs de la 5e édition
123. Population Pharmacokinetic Study of Amoxicillin-Treated Burn Patients Hospitalized at a Swiss Tertiary-Care Center
124. Amisulpride: Real-World Evidence of Dose Adaptation and Effect on Prolactin Concentrations and Body Weight Gain by Pharmacokinetic/Pharmacodynamic Analyses
125. Risk-benefit balance assessment of SSRI antidepressant use during pregnancy and lactation based on best available evidence – an update
126. Reply to L. Pala et al
127. Adherence to intermittent preventive treatment for malaria in Papua New Guinean infants: A pharmacological study alongside the randomized controlled trial
128. Using a structured reconciliation medication form improves medication transition from hospital to community care and primary care physicians’ adherence with medication adaptations and recommendations
129. Exploiting Pharmacokinetic Models of Tamoxifen and Endoxifen to Identify Factors Causing Subtherapeutic Concentrations in Breast Cancer Patients
130. Genetic, ethnic, and gender differences in the pharmacokinetics of antiretroviral agents
131. Population pharmacokinetics of fluconazole given for secondary prevention of oropharyngeal candidiasis in HIV-positive patients
132. Influence of Drug–Drug Interactions on the Pharmacokinetics of Atorvastatin and Its Major Active Metabolite ortho-OH-Atorvastatin in Aging People Living with HIV.
133. Contribution of Genetic Background and Data Collection on Adverse Events of Anti–human Immunodeficiency Virus (HIV) Drugs (D:A:D) Clinical Risk Score to Chronic Kidney Disease in Swiss HIV-infected Persons With Normal Baseline Estimated Glomerular Filtration Rate
134. Towards Personalized Antithrombotic Treatments: Focus on P2Y12 Inhibitors and Direct Oral Anticoagulants.
135. Effect of renal clearance and continuous renal replacement therapy on appropriateness of recommended meropenem dosing regimens in critically ill patients with susceptible life-threatening infections
136. Sex Differences in Efficacy and Toxicity of Systemic Treatments: An Undervalued Issue in the Era of Precision Oncology
137. Population Pharmacokinetic Study of Amoxicillin-Treated Burn Patients Hospitalized at a Swiss Tertiary-Care Center
138. Quantitative Analysis of Gentamicin Exposure in Neonates and Infants Calls into Question Its Current Dosing Recommendations
139. Evaluation of Exposure to Vancomycin in Neonates with Current Dosing Approaches
140. Quelle alternative aux benzodiazépines, Z-pills et autres hypnotiques pour les personnes âgées ?: Mélatonine, valériane ou clométhiazole
141. Challenging Recommended Oral and Intravenous Voriconazole Doses for Improved Efficacy and Safety: Population Pharmacokinetics-Based Analysis of Adult Patients With Invasive Fungal Infections
142. Bon usage des antidépresseurs ISRS durant la grossesse – le défi de l'évaluation de la balance bénéfice-risque
143. Simultaneous determination of selective serotonin reuptake inhibitors and their main metabolites in human breast milk by liquid chromatography-electrospray mass spectrometry
144. Détecter et évaluer l’impact desmédicaments anticholinergiques
145. Pharmacometrics-based decision tools facilitate mHealth implementation
146. Stereoselective determination of citalopram and desmethylcitalopram in human plasma and breast milk by liquid chromatography tandem mass spectrometry
147. Escitalopram population pharmacokinetics in people living with human immunodeficiency virus and in the psychiatric population: Drug–drug interactions and probability of target attainment.
148. Influence of body weight and UGT2B7 polymorphism on varenicline exposure in a cohort of smokers from the general population.
149. Complementary medicine use during cancer treatment and potential herb-drug interactions from a cross-sectional study in an academic centre.
150. Using a structured reconciliation medication form improves medication transition from hospital to community care and primary care physicians' adherence with medication adaptations and recommendations.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.